Late-Breaking Abstracts Announced for the Society for Immunotherapy of Cancer’s 37th Annual Meeting

Share Article

The Society for Immunotherapy of Cancer (SITC) received a record-breaking number of abstract submissions in 2022, more than 1,500, and has announced titles and authors for late-breaking abstracts (LBA). The abstracts will be presented at SITC’s upcoming 37th Annual Meeting & Pre-Conference Programs taking place November 8–12, 2022, in Boston, MA and virtually.

News Image
“SITC is excited to incorporate these abstracts into an already impressive group of abstracts. The late-breaking abstracts will round out the content offered at the 37th Annual Meeting and highlight more cutting-edge research and data,” said SITC President Patrick Hwu, MD.

The Society for Immunotherapy of Cancer (SITC) received a record-breaking number of abstract submissions in 2022, more than 1,500, and has announced titles and authors for late-breaking abstracts (LBA). The abstracts will be presented at SITC’s upcoming 37th Annual Meeting & Pre-Conference Programs taking place November 8–12, 2022, in Boston, MA and virtually.

“SITC is excited to incorporate these abstracts into an already impressive group of abstracts. The late-breaking abstracts will round out the content offered at the 37th Annual Meeting and highlight more cutting-edge research and data,” said SITC President Patrick Hwu, MD.

The late-breaking abstracts are:
(1468) First data readout of standardized transcriptional profiling for optimizing cellular therapies: A Multi-Center PICI-NanoString collaboration
Sarah Church, PhD – NanoString Technologies

(1469) A phase II basket trial of Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors (DART SWOG 1609 Cohort 47) in patients with gestational trophoblastic disease
Sandip Patel, MD – University of California San Diego Moores Cancer Center

(1470) Combining the antigen-presenting cell activator eftilagimod alpha (soluble LAG-3) and pembrolizumab: efficacy results from the 1st line non-small cell lung cancer cohort of TACTI-002 (Phase II)
Wade T. Iams, MD – Vanderbilt University Medical Center

(1471) Pharmacodynamic and predictive biomarkers associated with response in cancer patients treated with TPST-1120: a first-in-class, small molecule antagonist of Peroxisome-Proliferator Activated Receptor-Alpha
Nathan Standifer, PhD – Tempest Therapeutics

(1472) Assessing the Correlation between CD8 Cell PET Imaging with 89-Zr-Crefmirlimab Berdoxam and CD8 Cell Immunohistochemistry in Patients with Advanced Cancer Receiving Immunotherapy
Michael Postow, MD – Memorial Sloan Kettering Cancer Center

(1473) Mechanism of action of bempegaldesleukin (BEMPEG) plus nivolumab (NIVO) in patients with unresectable or metastatic melanoma from the phase 3 randomized open-label PIVOT IO-001 clinical trial
Celeste Lebbe, MD, PhD – Université Paris Cite, Dermatolo-Oncology AP-HP Hôpital Sain

(1474) Cancer Vaccine Plus PD-1 Blockade Promotes Infiltration of Melanoma Metastases by Vaccine-Induced T Lymphocytes
Christine Tran, MD – University of Virginia

(1475) A phase 1 study to characterize the safety and tolerability of MP0317, a tumor targeting FAP dependent CD40 agonist DARPin, in patients with relapsed/refractory solid tumors
Paul Baverel, PhD – Molecular Partners AG

(1477) First efficacy and multi-omic analysis data from phase 1 clinical trial of oncolytic viral immunotherapy with CAN-2409 + valacyclovir in combination with nivolumab and standard of care in newly diagnosed high-grade glioma.
Patrick Wen, MD – Dana Farber Cancer Institute

(1478) A phase I study of personalized adoptive TCR T cell therapy in patients with solid tumors: safety, efficacy, and T cell trafficking to tumors of non-virally gene edited T cells
Stefanie Mandl, PhD – PACT Pharma
Antoni Ribas, MD, PhD - University of California Los Angeles

The full abstracts will be available on Nov. 7 at 8 a.m. EST as a supplement published in the Journal for ImmunoTherapy of Cancer (JITC).

Late-Breaking Abstract Sessions with oral abstract presentations will take place on Thursday, Nov. 10 from 11:10–11:40 a.m. EST and Friday, Nov. 11 from 11:25–11:55 a.m. EST. Late-Breaking Abstract posters will be presented in the Poster Hall in Boston, MA and the virtual ePoster Hall beginning Thursday, Nov. 10 at 9 a.m. EST.

To learn more about the late-breaking abstracts, visit the 37th Annual Meeting & Pre-Conference Programs website.

About SITC
The Society for Immunotherapy of Cancer (SITC) is the world’s leading member-driven organization specifically dedicated to improving cancer patient outcomes by advancing the science and application of cancer immunotherapy. Established in 1984, SITC, a 501(c)(3) not-for-profit organization, serves scientists, clinicians, academicians, patients, patient advocates, government representatives and industry leaders from around the world. Through educational programs that foster scientific exchange and collaboration, SITC aims to one day make the word cure a reality for cancer patients everywhere. To learn more, visit http://www.sitcancer.org and follow us on Twitter, LinkedIn and YouTube.

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Thomas Martin
@sitcancer
Follow >
Visit website

Media